<DOC>
	<DOCNO>NCT02180100</DOCNO>
	<brief_summary>The objective study demonstrate comparable safety efficacy Terconazole Vaginal Suppositories , 80 mg fluconazole treatment subject severe vulvovaginal candidiasis .</brief_summary>
	<brief_title>Terconazole Vaginal Suppository vs Fluconazole Treatment Severe Vulvovaginal Candidiasis</brief_title>
	<detailed_description>This study demonstrate comparable safety efficacy Terconazole Vaginal Suppository 80 mg insert intravaginally daily bedtime 6 consecutive day oral fluconazole 150mg day 1 day 4 treatment subject severe vulvovaginal candidiasis .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Vulvovaginal</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Terconazole</mesh_term>
	<criteria>Vulvovaginal candidiasis infection diagnose , symptom evaluate use numerical rating system base severity ( absent=0 ; mild=1 ; moderate=2 ; severe=3 ) minimum VVC Composite Signs/Symptoms score 7 Subject completes inform consent process Subject agrees take study medication schedule Subject complies clinical trial instruction . Commits followup visit Subject agree abstain sexual intercourse time randomization first seven day immediately follow treatment sexually transmit disease gynaecological abnormality require treatment disease know predispose candidiasis diabetes mellitus , receive antibiotic corticosteriods use antifungal medication week entry ; expect menstruate within seven day start treatment infect one candida specie</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>